Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Lymphoblastic Lymphoma Clinical Trial

— LBL-CISL-1  

Official title:

The Clinical Outcomes of Hyper-CVAD Treatment in Lymphoblastic Lymphoma

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT01813344
• Other study ID #: LBL-CISL-1
• Status: Recruiting
• Phase: N/A
• First received: March 13, 2013
• Last updated: March 14, 2013
• Start date: January 2012

Study information

• Verified date: March 2013
• Source: Ajou University School of Medicine
• Contact: Seong Hyun Jeong, MD
• Phone: +82-31-219-5989
• Email: seonghyunmd[@]naver.com
• Is FDA regulated: No
• Health authority: Korea: Institutional Review Board
• Study type: Observational

Clinical Trial Summary

Treatment outcomes of lymphoblastic lymphoma (LBL) have improved by the use of the regimens for acute lymphoblastic leukemia. Hyper-CVAD is one of the most effective treatments with high remission rate in acute lymphoblastic leukemia (ALL) and LBL. However, the treatment outcome of hyper-CVAD in LBL has reported only in small number of patients from single institution. The investigators conducted this study to evaluate the hyper-CVAD regimen based treatment in LBL.

Description:

We will analyze treatment outcome of lymphoblastic lymphoma patients treated with hyper-CVAD regimen from 13 institutions in Korea. In all patients, hyper-CVAD was initial treatment. After achievement of response, patients either underwent hematopoietic stem cell transplantation (HSCT) or consolidation with hyper-CVAD.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 50
• Est. primary completion date: June 2013
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• age over 18 at diagnosis

• Pathologically proven lymphoblastic lymphoma

Exclusion Criteria:

• proven HIV infection

• pretreatment with other regimens

Study Design

Time Perspective: Retrospective

Related Conditions & MeSH terms

• Lymphoblastic Lymphoma
• Lymphoma
• Lymphoma, Non-Hodgkin

Locations

Country	Name	City	State
Korea, Republic of	Ajou Universtiy School of Medicine	Suwon	Kyeonggi

Sponsors (1)

Lead Sponsor	Collaborator
Ajou University School of Medicine

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Overall survival		3-year	No
Primary	Progression free survival		3-year	No
Secondary	Response Rate		24 weeks	No